Japan Tissue Engineering Co

Japan Tissue Engineering Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Japan Tissue Engineering Co (7774.T) as of Nov 20, 2026 is 66.42 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 58.11 % — a change of 14.29% (higher).

Cash Conversion

66.42 %

YoY

14.29%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Japan Tissue Engineering Co is 2026 66.42 % . Cash Conversion Rate (OCF/Net Income) of Japan Tissue Engineering Co was 2025 58.11 % . It decreases by 14.29% higher compared to the previous year.

The Japan Tissue Engineering Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2019
118.86 JPY
Jan 1, 2020
29.46 JPY
Jan 1, 2021
85.63 JPY
Jan 1, 2022
45.24 JPY
Jan 1, 2023
85.37 JPY
Jan 1, 2024
191.48 JPY
Jan 1, 2025
58.11 JPY
Jan 1, 2026
66.42 JPY
The Japan Tissue Engineering Co Cash Conversion history
YEARCash ConversionYoY
66.42 %+14.29%
58.11 %-69.65%
191.48 %+124.30%
85.37 %+88.70%
45.24 %-47.17%
85.63 %+190.66%
29.46 %-75.21%
118.86 %-57.14%
277.33 %+1,294.18%
19.89 %-60.92%
50.90 %-53.55%
109.59 %-5.63%
116.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Japan Tissue Engineering Co Stock analysis

What does Japan Tissue Engineering Co do? Japan Tissue Engineering Co., Ltd. generates revenue through three business segments. The Regenerative Medicine Product segment sells autologous cultured epidermis JACE and autologous cultured cartilage JACK to medical institutions. The Regenerative Medicine Outsourcing segment offers CDMO, CRO, consulting, and contract manufacturing services for cell processed products. The Research and Development Support segment sells human cultured tissues developed using the company's advanced culture technology. Medical institutions purchase regenerative medicine products, while pharmaceutical and biotech companies utilize outsourcing services for cell-based therapies. The company's products are sold to healthcare providers and research-focused clients across Japan and potentially internationally. The Regenerative Medicine Product segment focuses on selling JACE and JACK, which are used in medical treatments requiring tissue regeneration. These products are specifically designed for autologous use, meaning they are derived from the patient's own cells. The Outsourcing segment provides specialized services to support the development and manufacturing of cell-based therapies, targeting pharmaceutical and biotech firms. The Research and Development Support segment supplies tissues for research applications, leveraging the company's internal technology to meet client needs in scientific development. JACE and JACK are key products in the Regenerative Medicine Product segment, directly sold to medical institutions for clinical use. The Outsourcing segment serves as a service provider for cell therapy development, offering CDMO and CRO capabilities. The Research and Development Support segment's human cultured tissues are marketed to research organizations seeking advanced cell culture solutions. All segments contribute to the company's revenue by addressing specific needs in regenerative medicine and cell therapy development. Japan Tissue Engineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Japan Tissue Engineering Co stock

Cash Conversion Rate (OCF/Net Income) of Japan Tissue Engineering Co is 66.42 % in 2026.

Cash Conversion Rate (OCF/Net Income) of Japan Tissue Engineering Co changed from 58.11 % to 66.42 %, representing a 14.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Japan Tissue Engineering Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Japan Tissue Engineering Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Japan Tissue Engineering Co

All Key Metrics — Japan Tissue Engineering Co